jCell (RPCs)
Diabetic Retinopathy
PreclinicalActive
Key Facts
About jCyte
jCyte is a private, pre-revenue biotech advancing a proprietary platform of retinal progenitor cell (RPC) therapies for inherited retinal diseases. Its lead asset, jCell, is in late-stage clinical development for retinitis pigmentosa, with a pivotal Phase 3 trial (JC02-88) now enrolling. The company leverages its RPC platform to pursue multiple ophthalmic indications, including diabetic retinopathy, positioning it in the high-need cell and gene therapy space for blindness. Leadership combines strong scientific co-founders with experienced biotech executives to drive clinical and corporate strategy.
View full company profileTherapeutic Areas
Other Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (DR) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |